Cargando…
Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial()()
BACKGROUND: Cutaneous warts are caused by a small group of specific types of human papillomaviruses. Cryotherapy is a highly effective treatment for patients with viral warts; however, it is a painful method and usually requires several treatment sessions. Zinc is a trace element with many proven ef...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986231/ https://www.ncbi.nlm.nih.gov/pubmed/29872682 http://dx.doi.org/10.1016/j.ijwd.2017.09.004 |
_version_ | 1783328886959898624 |
---|---|
author | Mahmoudi, H. Ghodsi, S.Z. Tavakolpour, S. Daneshpazhooh, M. |
author_facet | Mahmoudi, H. Ghodsi, S.Z. Tavakolpour, S. Daneshpazhooh, M. |
author_sort | Mahmoudi, H. |
collection | PubMed |
description | BACKGROUND: Cutaneous warts are caused by a small group of specific types of human papillomaviruses. Cryotherapy is a highly effective treatment for patients with viral warts; however, it is a painful method and usually requires several treatment sessions. Zinc is a trace element with many proven effects on the immune system. OBJECTIVE: Our aim was to assess the efficacy and safety of oral zinc sulfate in the treatment and recurrence rate of common warts. METHODS: Eighty-three patients with common warts participated in this double-blind, randomized, placebo-controlled trial. In both groups, three sessions of liquid nitrogen cryotherapy were performed for up to 2 months with 3-week intervals. The treatment group (n = 45) received oral zinc sulfate capsules in a dose of 10 mg/kg per day up to 600 mg day. The control group (n = 38) was provided with placebo of similar appearance. Treatment continued for 2 months and the follow-up period lasted up to 6 months. RESULTS: Warts completely resolved in 26 patients in the treatment group (68.4%) and 23 patients in the placebo group (63.9%; p = .68). Three patients (7.9%) in the treatment group and six patients (16.6%) in the placebo group has a recurrence of the warts (p = .19). CONCLUSION: According to our study, the addition of zinc to cryotherapy was not beneficial in the treatment of patients with common warts nor did it prevent recurrences. |
format | Online Article Text |
id | pubmed-5986231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-59862312018-06-05 Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial()() Mahmoudi, H. Ghodsi, S.Z. Tavakolpour, S. Daneshpazhooh, M. Int J Womens Dermatol Article BACKGROUND: Cutaneous warts are caused by a small group of specific types of human papillomaviruses. Cryotherapy is a highly effective treatment for patients with viral warts; however, it is a painful method and usually requires several treatment sessions. Zinc is a trace element with many proven effects on the immune system. OBJECTIVE: Our aim was to assess the efficacy and safety of oral zinc sulfate in the treatment and recurrence rate of common warts. METHODS: Eighty-three patients with common warts participated in this double-blind, randomized, placebo-controlled trial. In both groups, three sessions of liquid nitrogen cryotherapy were performed for up to 2 months with 3-week intervals. The treatment group (n = 45) received oral zinc sulfate capsules in a dose of 10 mg/kg per day up to 600 mg day. The control group (n = 38) was provided with placebo of similar appearance. Treatment continued for 2 months and the follow-up period lasted up to 6 months. RESULTS: Warts completely resolved in 26 patients in the treatment group (68.4%) and 23 patients in the placebo group (63.9%; p = .68). Three patients (7.9%) in the treatment group and six patients (16.6%) in the placebo group has a recurrence of the warts (p = .19). CONCLUSION: According to our study, the addition of zinc to cryotherapy was not beneficial in the treatment of patients with common warts nor did it prevent recurrences. Elsevier 2017-10-20 /pmc/articles/PMC5986231/ /pubmed/29872682 http://dx.doi.org/10.1016/j.ijwd.2017.09.004 Text en © 2017 Published by Elsevier Inc. on behalf of Women's Dermatologic Society. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Mahmoudi, H. Ghodsi, S.Z. Tavakolpour, S. Daneshpazhooh, M. Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial()() |
title | Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial()() |
title_full | Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial()() |
title_fullStr | Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial()() |
title_full_unstemmed | Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial()() |
title_short | Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial()() |
title_sort | cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: a double blind, randomized, placebo-controlled trial()() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986231/ https://www.ncbi.nlm.nih.gov/pubmed/29872682 http://dx.doi.org/10.1016/j.ijwd.2017.09.004 |
work_keys_str_mv | AT mahmoudih cryotherapyplusoralzincsulfateversuscryotherapyplusplacebototreatcommonwartsadoubleblindrandomizedplacebocontrolledtrial AT ghodsisz cryotherapyplusoralzincsulfateversuscryotherapyplusplacebototreatcommonwartsadoubleblindrandomizedplacebocontrolledtrial AT tavakolpours cryotherapyplusoralzincsulfateversuscryotherapyplusplacebototreatcommonwartsadoubleblindrandomizedplacebocontrolledtrial AT daneshpazhoohm cryotherapyplusoralzincsulfateversuscryotherapyplusplacebototreatcommonwartsadoubleblindrandomizedplacebocontrolledtrial |